elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
PARP inhibitor
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
PARP inhibitor
RIS
0.002
(Research Intensity Score)
Papers
243
Top papers
Ovarian Cancer
2025 · 308 citations
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019 · 2231 citations
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2018 · 2874 citations
A new wave of innovations within the DNA damage response
2023 · 136 citations
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
2023 · 118 citations
Newest papers
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
2026 · 4 citations
PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma
2026 · 3 citations
Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis
2026 · 3 citations
Synthesis and Preliminary Evaluation of the 211 At-Labeled PARP Inhibitor [ 211 At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic
2026 · 2 citations
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)
2026 · 2 citations
A sample from the 100 top papers behind PARP inhibitor.
Create a free account to browse them all →
PARP inhibitor's history
Research intensity over time
Explore PARP inhibitor's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
PARP inhibitor's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link